A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments ...

Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.

BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis ...

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest CRO, CMIC, to improve the ability ...

Mendaera has raised $73 million in venture capital funding to continue the development of its handheld robotics platform for ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

The NIH has found evidence of research misconduct against Eliezer Masliah, M.D., the longtime head of the National Institute ...

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners ...